Terapi Fibrinolitik Pada Pasien St-Segment Elevation Myocardial Infarction (Stemi) : Review Artikel
FIBRINOLITIC THERAPY IN PATIENTS OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) : A REVIEW
Abstract
Acute ST-elevation myocardial infarction (STEMI) occurs when there is a blockage caused by sudden atherosclerotic plaque that blocks blood flow to the heart. The goal of STEMI therapy is to restore myocardial blood flow, to save the heart. Coronary arterial reproduction recommended by the American Heart Association (AHA) and the Indonesian Cardiovascular Specialist Association (PERKI) is primary percutaneous coronary intervention (PCI) or fibrinolytic. However, not all hospitals have catheterization laboratory facilities, so they still use fibrinolytic as reperfusion therapy. To provide a review of currently available fibrinolytic therapies that can be used in STEMI patients. Four databases [Pubmed, Libgen, researchgate, and Scopus] were searched from 1987 to 2019. Include original articles including RCT, comparative, literature review, and observational study about fibrinolytics treatment in Acute STEMI. Fibrinolytic was divided into specific fibrin (alteplase, tenecteplase, and reteplase) and non-specific fibrin (streptokinase and urokinase). Fibrinolytic used in STEMI are streptokinase, alteplase, tenecteplase, and reteplase. Fibrinolytic can be given when the patient has no contraindications. Furthermore, the administration must follow protocols to minimize the risk of side effects such as bleeding. Fibrinolytic can be used as reperfusion therapy in STEMI patients when PCI cannot be done promptly.
Downloads
Download data is not yet available.
References
Ali, M.R. et al., 2014. Aspect of thrombolytic therapy: A review. Scientific World Journal, 2014(1).
2. Antmann, E., Braunwald, E. & Loscalzo, J., 2010. ST Segment Eelevation Myocardial Infarction. In Harisson’s Cardiovascular Medicine. New york: Mc Graw Hill Inc.
3. Baskin, J. et al., 2012. Thrombolytic therapy for central venous catheter occlusion. Haematologica, 97(5), pp.641-50.
4. Bendary, A., Tawfik, W., Mahrous, M. & Salem, M., 2017. Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen. Journal of Cardiovascular and Thoracic Research, 9(4).
5. Candelise, L. et al., 1996. Thrombolytic therapy From myocardial to cerebral infarction. Ital. J. Neurol. Sci, 17, pp.5-21.
6. Chang, L. & Yeh, R., 2014. Evaluation and Management of ST-elevation Myocardial Infarction and Shock. European Cardiology Review, 9(2), pp.88-91.
7. Churchhouse, A. & Ormerod, J., 2017. Infark Miokard Akut. In H. Kalim, ed. Kardiologi dan Kelainan Vaskular. 1st ed. Singapore: Elsevier. pp.177-93.
8. Daga, L.C., Kaul, U. & Mansoor, A., 2011. Approach to STEMI and NSTEMI. SUPPLEMENT TO JAPI • decem ber 2011 • VOL. 59, 59, pp.19-25.
9. Dipiro, J. et al., 2009. Acute Coronary Syndrome. In Pharmacotherapy: A Pathophysiologic Approach. 8th ed. United States: McGraw-Hill Education. pp.642-575.
10. Fox, K., White, H.D., Gersh, B. & Opie, L.H., 2013. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In Drugs For The Heart. Eighth Edition ed. Philadelphia: Saunders Elsevier Inc. pp.378-87.
11. Ghaffari, S., Kazemi, B. & Golzari, I.G., 2013. Efficacy of a New Accelerated Streptokinase Regime in Acute Myocardial Infarction: A Double Blind Randomized Clinical Trial. Cardiovascular Therapeutics, 31(1).
12. GISSI-2, 1990. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. THE LANCET, 336.
13. Gulati, R. & Gersh, B.J., 2009. Antithrombotic Therapy for the Prevention of Reinfarction After Reperfusion Therapy: The Price of Success. Revista Española de Cardiología (English Edition), 62(5).
14. Hendersoni, M., Carberry, J. & Colin, B., 2019. Targeting an Ischemic Time Journal of the American Heart Association, 8, pp.1-4.
15. Hermanides, R.S., Kilic, S. & Van’t Hof, A.W.J., 2018. Optimal pharmacological therapy in ST-elevation myocardial infarction—a review: A review of antithrombotic therapies in STEMI. Neth Heart Journal, 26(6).
16. Ibanez, B. et al., 2018. 2017 ESC Guidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 39, pp.119-77.
17. Jinatongthai, P. et al., 2017. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet, 390(10096).
18. Kasper, D.L. et al., 2016. ST-Segmen Elevation Miocardial Infarction. In Harrison's Manual Of Medicine. 19th ed. New York: McGraw-Hill Education. pp.658-67.
19. Laksono, B.B., 2015. Literatur Review Efektifitas Terapi Dan PPCI (Primary Percutaneus Corornary Intervention) Sebagai Alternative Terpi Revaskulerisasi Pada Acute Coronary Syndrome (ACS). Jurnal Kesehatan Hesti Wira Sakti, 3(3).
20. Nazari, J., Davidson, R., Kaplan, K. & Fintel, D., 1987. Adverse Reactions to Thrombolytic Agents Implicationsfor Coronary Reperfusion Following Myocardia lInfarction. Medica lToxicology, 2, p.27286.
21. Newby, D.E., Grubb, N.R. & Bradbury, A., 2010. Cardiovascular Disease. In N.R. Colledge, B.R. Walker & B.H. Ralston, eds. Davidson's Principle and Practice of Medicine. 21st ed. Edinburgh: Elsevier. pp.577-98.
22. O’Gara, P.T. et al., 2013. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation, 127(4).
23. Pandie, S., Hellenberg, D., Hellig, F. & Ntsekhe, M., 2016. Approach to chest pain and acute myocardial infarction. South African Medical Journal, 106(3).
24. PERKI, Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia., 2015. Pedoman Penatalaksanaan SIndrom Koroner Akut. Jurnal Kardiologi Indonesia.
25. Pu, J. et al., 2017. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment–Elevation Myocardial Infarction. Circulation, 136.
26. Rathore, .V., Singh, N. & Mahat, R.K., 2018. Risk Factors for Acute Myocardial Infarction: A Review. EJMI, 2(1), pp.1-7.
27. Sampson, A.J., Paul, T. & Stouffer, G.A., 2015. Pharmacological Therapy in The Management of Acute Coronary Syndromes. In H. Wang & C. Patterson, eds. Atherosclerosis: Risks, Mechanisms, and Therapies. First Edition ed. NC, USA: John Wiley & Sons, Inc. pp.517-31.
28. Sekhar, G.R. et al., 2017. A Review on Thrombolytic Therapy used in Myocardial Infarction (Streptokinase vs Tenecteplase). Int. J. Pharm. Sci. Rev. Res, 45(2), pp.29-32.
29. The GUSTO, I., 1993. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med, 329(10), pp.673– 682.
30. Thomas, K.N. & Christoph, B., 2015. Thrombolytic Agents And Their Role In Clinical Medicine. BMJ
31. Varma, A., Chillawar, S., Kamble, T. & Acharya, S., 2016. Clinical Markers of Reperfusion in Patients with Acute Myocardial Infarction and Its Prognostic Significance. Int J Recent Surg Med Sci 2016;2(2):90-95., 02(02).
32. Vivek, L., 2017. Fibrinolytic Drug Therapy in the Management of Intravascular Thrombosis, Especially Acute Myocardial Infarction - A Review. J of Pharmacol & Clin Res, 2(4), pp.001-05.
33. Werf, V.d., 2012. Recommendations for an efficient and safe use of fibrinolytic agents. The Bangkok Medical Journal, 3, pp.68-78.
2. Antmann, E., Braunwald, E. & Loscalzo, J., 2010. ST Segment Eelevation Myocardial Infarction. In Harisson’s Cardiovascular Medicine. New york: Mc Graw Hill Inc.
3. Baskin, J. et al., 2012. Thrombolytic therapy for central venous catheter occlusion. Haematologica, 97(5), pp.641-50.
4. Bendary, A., Tawfik, W., Mahrous, M. & Salem, M., 2017. Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen. Journal of Cardiovascular and Thoracic Research, 9(4).
5. Candelise, L. et al., 1996. Thrombolytic therapy From myocardial to cerebral infarction. Ital. J. Neurol. Sci, 17, pp.5-21.
6. Chang, L. & Yeh, R., 2014. Evaluation and Management of ST-elevation Myocardial Infarction and Shock. European Cardiology Review, 9(2), pp.88-91.
7. Churchhouse, A. & Ormerod, J., 2017. Infark Miokard Akut. In H. Kalim, ed. Kardiologi dan Kelainan Vaskular. 1st ed. Singapore: Elsevier. pp.177-93.
8. Daga, L.C., Kaul, U. & Mansoor, A., 2011. Approach to STEMI and NSTEMI. SUPPLEMENT TO JAPI • decem ber 2011 • VOL. 59, 59, pp.19-25.
9. Dipiro, J. et al., 2009. Acute Coronary Syndrome. In Pharmacotherapy: A Pathophysiologic Approach. 8th ed. United States: McGraw-Hill Education. pp.642-575.
10. Fox, K., White, H.D., Gersh, B. & Opie, L.H., 2013. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In Drugs For The Heart. Eighth Edition ed. Philadelphia: Saunders Elsevier Inc. pp.378-87.
11. Ghaffari, S., Kazemi, B. & Golzari, I.G., 2013. Efficacy of a New Accelerated Streptokinase Regime in Acute Myocardial Infarction: A Double Blind Randomized Clinical Trial. Cardiovascular Therapeutics, 31(1).
12. GISSI-2, 1990. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. THE LANCET, 336.
13. Gulati, R. & Gersh, B.J., 2009. Antithrombotic Therapy for the Prevention of Reinfarction After Reperfusion Therapy: The Price of Success. Revista Española de Cardiología (English Edition), 62(5).
14. Hendersoni, M., Carberry, J. & Colin, B., 2019. Targeting an Ischemic Time Journal of the American Heart Association, 8, pp.1-4.
15. Hermanides, R.S., Kilic, S. & Van’t Hof, A.W.J., 2018. Optimal pharmacological therapy in ST-elevation myocardial infarction—a review: A review of antithrombotic therapies in STEMI. Neth Heart Journal, 26(6).
16. Ibanez, B. et al., 2018. 2017 ESC Guidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 39, pp.119-77.
17. Jinatongthai, P. et al., 2017. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis. Lancet, 390(10096).
18. Kasper, D.L. et al., 2016. ST-Segmen Elevation Miocardial Infarction. In Harrison's Manual Of Medicine. 19th ed. New York: McGraw-Hill Education. pp.658-67.
19. Laksono, B.B., 2015. Literatur Review Efektifitas Terapi Dan PPCI (Primary Percutaneus Corornary Intervention) Sebagai Alternative Terpi Revaskulerisasi Pada Acute Coronary Syndrome (ACS). Jurnal Kesehatan Hesti Wira Sakti, 3(3).
20. Nazari, J., Davidson, R., Kaplan, K. & Fintel, D., 1987. Adverse Reactions to Thrombolytic Agents Implicationsfor Coronary Reperfusion Following Myocardia lInfarction. Medica lToxicology, 2, p.27286.
21. Newby, D.E., Grubb, N.R. & Bradbury, A., 2010. Cardiovascular Disease. In N.R. Colledge, B.R. Walker & B.H. Ralston, eds. Davidson's Principle and Practice of Medicine. 21st ed. Edinburgh: Elsevier. pp.577-98.
22. O’Gara, P.T. et al., 2013. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation, 127(4).
23. Pandie, S., Hellenberg, D., Hellig, F. & Ntsekhe, M., 2016. Approach to chest pain and acute myocardial infarction. South African Medical Journal, 106(3).
24. PERKI, Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia., 2015. Pedoman Penatalaksanaan SIndrom Koroner Akut. Jurnal Kardiologi Indonesia.
25. Pu, J. et al., 2017. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment–Elevation Myocardial Infarction. Circulation, 136.
26. Rathore, .V., Singh, N. & Mahat, R.K., 2018. Risk Factors for Acute Myocardial Infarction: A Review. EJMI, 2(1), pp.1-7.
27. Sampson, A.J., Paul, T. & Stouffer, G.A., 2015. Pharmacological Therapy in The Management of Acute Coronary Syndromes. In H. Wang & C. Patterson, eds. Atherosclerosis: Risks, Mechanisms, and Therapies. First Edition ed. NC, USA: John Wiley & Sons, Inc. pp.517-31.
28. Sekhar, G.R. et al., 2017. A Review on Thrombolytic Therapy used in Myocardial Infarction (Streptokinase vs Tenecteplase). Int. J. Pharm. Sci. Rev. Res, 45(2), pp.29-32.
29. The GUSTO, I., 1993. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med, 329(10), pp.673– 682.
30. Thomas, K.N. & Christoph, B., 2015. Thrombolytic Agents And Their Role In Clinical Medicine. BMJ
31. Varma, A., Chillawar, S., Kamble, T. & Acharya, S., 2016. Clinical Markers of Reperfusion in Patients with Acute Myocardial Infarction and Its Prognostic Significance. Int J Recent Surg Med Sci 2016;2(2):90-95., 02(02).
32. Vivek, L., 2017. Fibrinolytic Drug Therapy in the Management of Intravascular Thrombosis, Especially Acute Myocardial Infarction - A Review. J of Pharmacol & Clin Res, 2(4), pp.001-05.
33. Werf, V.d., 2012. Recommendations for an efficient and safe use of fibrinolytic agents. The Bangkok Medical Journal, 3, pp.68-78.
Published
2021-07-02
How to Cite
NOVRIANTI, Irma; ., Heriani; F, Mustamin.
Terapi Fibrinolitik Pada Pasien St-Segment Elevation Myocardial Infarction (Stemi) : Review Artikel.
Jurnal Farmasi Udayana, [S.l.], p. 55-67, july 2021.
ISSN 2622-4607.
Available at: <https://ojs.unud.ac.id/index.php/jfu/article/view/61374>. Date accessed: 21 nov. 2024.
doi: https://doi.org/10.24843/JFU.2021.v10.i01.p07.
Section
Articles
